FineMark National Bank & Trust boosted its position in Celgene Co. (NASDAQ:CELG) by 11.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 51,548 shares of the biopharmaceutical company’s stock after acquiring an additional 5,194 shares during the period. FineMark National Bank & Trust’s holdings in Celgene were worth $4,863,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Bruderman Asset Management LLC acquired a new position in shares of Celgene in the 4th quarter valued at $25,000. Murphy Pohlad Asset Management LLC acquired a new position in shares of Celgene in the 4th quarter valued at $25,000. Athena Capital Advisors LLC acquired a new position in shares of Celgene in the 4th quarter valued at $27,000. Investors Research Corp acquired a new position in shares of Celgene in the 1st quarter valued at $28,000. Finally, Liberty Wealth Management LLC acquired a new position in shares of Celgene in the 4th quarter valued at $29,000. 70.78% of the stock is owned by hedge funds and other institutional investors.

CELG has been the topic of a number of research analyst reports. Cowen initiated coverage on shares of Celgene in a report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price target on the stock. Mizuho set a $103.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Friday, April 5th. William Blair lowered shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Monday, April 1st. ValuEngine upgraded shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Finally, Cantor Fitzgerald lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 target price on the stock. in a report on Friday, April 5th. Eighteen equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Celgene presently has a consensus rating of “Hold” and a consensus price target of $95.56.

NASDAQ:CELG opened at $95.24 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42. The firm has a market cap of $67.54 billion, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $97.07.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.05 EPS. Sell-side analysts forecast that Celgene Co. will post 9.85 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Holdings Increased by FineMark National Bank & Trust” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2019/05/25/celgene-co-celg-holdings-increased-by-finemark-national-bank-trust.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.